Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi, Giulia C

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. [electronic resource] - Journal of immunotherapy (Hagerstown, Md. : 1997) - 249-251 p. digital

Publication Type: Case Reports; Journal Article

1537-4513

10.1097/CJI.0000000000000173 doi


Aged
Antibodies, Monoclonal, Humanized--adverse effects
Antineoplastic Agents--adverse effects
Autoantibodies--blood
Carcinoma, Non-Small-Cell Lung--complications
Diabetic Ketoacidosis--diagnosis
Drug-Related Side Effects and Adverse Reactions--diagnosis
Glutamate Decarboxylase--immunology
Humans
Immunotherapy--adverse effects
Insulin--therapeutic use
Lung Neoplasms--complications
Male
Programmed Cell Death 1 Receptor--immunology
Remission Induction